## IONS: Ionis Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -0.5% below STRENGTH zone (4.0-10.0%); PEG 25.70 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: declining volume (54% of avg), momentum weakening (-6.2% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($73.62)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Can Ionis Pharmaceuticals Stock Hold Up When Markets Turn?**
- Source: Trefis | 20251208T080943 | Neutral | Relevance: 98%
- The article discusses the recent surge in Ionis Pharmaceuticals stock and raises questions about its potential performance during market downturns. It speculates on whether the stock can maintain its value if market conditions become less favorable.

**2. Kennedy Capital Management LLC Has $5.22 Million Position in Ionis Pharmaceuticals, Inc. $IONS**
- Source: MarketBeat | 20251207T042136 | Neutral | Relevance: 97%
-  Kennedy Capital Management LLC reduced its stake in Ionis Pharmaceuticals (NASDAQ:IONS) by 12.2% in the second quarter, now holding 132,045 shares valued at $5.22 million. Despite insider selling activity, Ionis Pharmaceuticals exceeded revenue and EPS expectations, and analysts maintain a "Moderate Buy" rating with an average target price of $84.15. The article details institutional ownership changes, insider sales, and recent financial performance.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | B of A Securiti | $97 | $86 | +13% |
| 2025-11-10 | HC Wainwright & | $110 | $100 | +10% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | B of A Securiti | main | Buy |
| 2025-11-10 | HC Wainwright & | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 13 ($8.92M) |
| Sells | 21 ($5.86M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.1% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- FMR, LLC: 14.6% (+0.2%)
- Vanguard Group Inc: 10.2% (-1.4%)
- T. Rowe Price Invest: 8.1% (-18.0%)
- Capital World Invest: 7.8% (+1.5%)
- Blackrock Inc.: 6.5% (-4.1%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-6.2% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $5.9M in recent transactions.
3. Valuation stretched: PEG 25.7x requires aggressive growth execution.
4. Elevated short interest (11.6%): bears positioning against stock.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 25.70 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.8x). Analyst sentiment positive (2 raises, avg +11%). Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $12.8B |
| Beta | 0.30 |
| 52W Range | $23.95 - $83.61 |
| Short Interest | 11.6% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 25.70 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 5.7% to -0.5% (-6.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 4.5pp (needs >4.0% for momentum thesis). Outperforming sector by 4.1pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 56. Volume at 54% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.47% (CS: 56) | Neutral |
| RSI_14 | 55.7 | Neutral |
| MACD Histogram | -0.09 | Bearish |
| vs SMA20 | 1.017x | Above |
| vs SMA50 | 1.068x | Above |
| vs SMA200 | 1.643x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $78.86
- **Stop Loss:** $73.62 (6.6% risk)
- **Target:** $84.10 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 57
- **Position Value:** $4,495.02
- **Portfolio %:** 4.50%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-18 (Est: $-1.20)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.05 | $-0.61 | +41.8% |
| 2025Q2 | $0.16 | $0.85 | +415.1% |
| 2025Q1 | $-1.03 | $-0.92 | +10.4% |
| 2024Q4 | $-0.84 | $-0.43 | +49.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*